Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G C Jayson

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2N C Ton, G J M Parker, A Jackson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsD J Jonker, L S Rosen, M B Sawyer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2019
Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trialF E Marti Marti, G C Jayson, P Manoharan, et al.
ESMO Open|February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trialJ A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
British Journal of Cancer|May 5, 2005
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendationsM O Leach, K M Brindle, J L Evelhoch, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2N C Ton, G J M Parker, A Jackson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsD J Jonker, L S Rosen, M B Sawyer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2019
Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trialF E Marti Marti, G C Jayson, P Manoharan, et al.
ESMO Open|February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trialJ A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
British Journal of Cancer|May 5, 2005
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendationsM O Leach, K M Brindle, J L Evelhoch, et al.
British Journal of Cancer|December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practiceM Adams, A H Calvert, J Carmichael, et al.
Pageof 7